Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients

OBJECTIVE: To evaluate the magnitude of humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with cancer receiving active therapies. PATIENTS AND METHODS: Patients 18 years or older in whom SARS-CoV-2 spike antibody (anti-S Ab) le...

Descripción completa

Detalles Bibliográficos
Autores principales: Chumsri, Saranya, Advani, Pooja P., Pai, Tanmayi S., Li, Zhuo, Mummareddy, Ashita, Acampora, Marites, Reynolds, Gina A., Wylie, Natasha, Boyle, Ashton W., Lou, Yanyan, Mody, Kabir, Moreno-Aspitia, Alvaro, Swift, Melanie D., Virk, Abinash, Bharucha, Adil E., Marquez, Christopher P., Patel, Tushar C., Gores, Gregory J., Knutson, Keith L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666324/
https://www.ncbi.nlm.nih.gov/pubmed/34926993
http://dx.doi.org/10.1016/j.mayocpiqo.2021.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666324/
https://www.ncbi.nlm.nih.gov/pubmed/34926993
http://dx.doi.org/10.1016/j.mayocpiqo.2021.12.004

Ejemplares similares